Addex Therapeutics Ltd (SWX:ADXN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 6.80M +16.0% |
| Revenue (ttm) | 172.86K -57.8% |
| Net Income | -6.73M |
| EPS | -0.06 |
| Shares Out | 147.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,596 |
| Open | 0.0454 |
| Previous Close | 0.0454 |
| Day's Range | 0.0440 - 0.0460 |
| 52-Week Range | 0.0336 - 0.0850 |
| Beta | 1.98 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 15, 2026 |
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mG... [Read more]
Financial Performance
Financial StatementsNews
Addex Therapeutics Earnings Call Transcript: H2 2025
Significant pipeline progress was made in chronic cough and brain injury recovery programs, with robust preclinical results and new clinical preparations. Financials show reduced cash burn and a cash runway through mid-2026, but further funding is needed for unpartnered programs.
Addex Therapeutics Annual report: H2 2025
Addex Therapeutics has published its H2 2025 annual report on April 30, 2026.
Addex Therapeutics Earnings release: H2 2025
Addex Therapeutics released its H2 2025 earnings on April 30, 2026, summarizing the period's financial results.
Addex Therapeutics Earnings release: H2 2025
Addex Therapeutics released its H2 2025 earnings on April 30, 2026, summarizing the period's financial results.
Addex Therapeutics Annual report: H2 2025
Addex Therapeutics has published its H2 2025 annual report on April 30, 2026.
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury r...
Addex Therapeutics (ADXN) Reveals Promising Preclinical Results for Chronic Cough Treatment
Addex Therapeutics (ADXN) Reveals Promising Preclinical Results for Chronic Cough Treatment
Addex Therapeutics announces GABAB PAM candidate data
Addex Therapeutics (ADXN) announced preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator candidate in a bleomycin-induced idiopathic pulmonary fibrosis exacer...
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a por...
Addex Therapeutics (ADXN) Sees Progress with Neurosterix's Clinical Study
Addex Therapeutics (ADXN) Sees Progress with Neurosterix's Clinical Study
Addex Therapeutics says spin-out company to complete NTX-253 study in Q2
Addex Therapeutics (ADXN) announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2. NTX-253 is an investigational potent, selective...
Addex Reports Strong Anti-Tussive For GABAB PAM Candidate
(RTTNews) - Addex Therapeutics (ADXN) has reported robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human prim...
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a por...
Addex Therapeutics Ltd – ADR trading resumes
12:01 EDT Addex Therapeutics (ADXN) Ltd – ADR trading resumes
Addex Therapeutics Ltd – ADR trading halted, volatility trading pause
11:56 EDT Addex Therapeutics (ADXN) Ltd – ADR trading halted, volatility trading pause
Addex Therapeutics (ADXN) Publishes Promising Research on Anxiety Treatment
Addex Therapeutics (ADXN) Publishes Promising Research on Anxiety Treatment
Addex publishes negative allosteric modulators data in Molecular Psychiatry
Addex Therapeutics (ADXN) announced publication of data in Molecular Psychiatry demonstrating that targeting metabotropic glutamate receptor 7 with negative allosteric modulators could be transformati...
Addex Therapeutics Ltd – ADR trading resumes
12:25 EST Addex Therapeutics (ADXN) Ltd – ADR trading resumes
Addex Therapeutics Ltd – ADR trading halted, volatility trading pause
12:15 EST Addex Therapeutics (ADXN) Ltd – ADR trading halted, volatility trading pause
Addex Therapeutics (ADXN) Advances NTX-253 into Clinical Trials for Schizophrenia
Addex Therapeutics (ADXN) Advances NTX-253 into Clinical Trials for Schizophrenia
Addex Therapeutics spin-out Neurosterix starts NTX-253 study
Addex Therapeutics (ADXN) announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is an orally available positive allosteric modulator of the muscari...
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a p...
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfo...
Addex Therapeutics Earnings Call Transcript: Q3 2025
Advanced GABAB PAM and Dipraglurant programs made significant preclinical progress, with robust efficacy data and strong patent positions. Cash runway extends to mid-2026, but further funding is needed for unpartnered clinical programs.
Addex Therapeutics Quarterly report: Q3 2025
Addex Therapeutics has published its Q3 2025 quarterly earnings report on December 4, 2025.